Poland drug reimbursement process explained

In Poland, the process of drug reimbursement involves several stages to determine if public funds will cover the cost of a medication. While a drug may be approved for market circulation based on its quality, efficacy, and safety, this does not automatically guarantee reimbursement.

To qualify for reimbursement, the benefits of a treatment must be assessed and compared against existing therapies. Authorities must also estimate the potential impact on the public budget and negotiate financing conditions. The Agency for Health Technology Assessment and Tariff System (AOTMiT) plays a key role in providing recommendations during this process.

Patients can access reimbursed medications through various channels, including pharmacy reimbursement, specific drug programs that define eligibility and required medical tests, or through chemotherapy catalogs. The specific reimbursement indication determines which patients can access a drug, even if it is on the official reimbursement list.